Santhera Pharmaceuticals Holding AG announced that it has signed an agreement with Ewopharma to launch Raxone(®) for the treatment of leber's hereditary optic neuropathy (LHON) in a number of Eastern European countries (Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Slovakia and Slovenia) and the Baltics (Estonia, Latvia and Lithuania). LHON is a rare, heritable, mitochondrial disease that leads to rapid, profound and usually permanent blindness in otherwise healthy patients. Raxone is the first treatment option for LHON and the first approved therapy for a mitochondrial disease.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.54 CHF | +3.52% |
|
+2.03% | -12.95% |
06-19 | Transcript : Santhera Pharmaceuticals Holding AG - Special Call | |
06-18 | Santhera Secures CHF69 Million Financing for Bond Repayment, Cash Runway Extension | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.95% | 84.96M | |
+6.87% | 72.01B | |
+33.71% | 10.39B | |
+40.84% | 5.26B | |
-18.53% | 4.64B | |
+12.65% | 3.7B | |
+27.58% | 2.3B | |
-39.96% | 1.8B | |
-45.87% | 1.7B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SANN Stock
- News Santhera Pharmaceuticals Holding AG
- Santhera Pharmaceuticals Holding AG Signs Distribution and Supply Agreement for Raxone with Ewopharma Covering Eastern Europe and the Baltics